Exploring Side Effects: Navigating the Balance The introduction of any medication, including Retatrutide, comes with considering potential side effects
TRIUMPH-CVOT, the cardiovascular outcomes trial in roughly 10,000 patients with established cardiovascular disease, is not expected to report until 2028 or 2029, but interim safety reviews matter
Retatrutide is often discussed beside GLP-1 and dual incretin medicines because all three approaches affect appetite and metabolism in different ways
Key takeaways Peptides are short chains of amino acids (which are building blocks of protein) that can act as signaling molecules in the body
It may become especially relevant for patients with fatty-liver-related metabolic disease
Wegovy (semaglutide) injection, for subcutaneous use